论文部分内容阅读
目的探讨替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌的临床效果。方法抽取2013年1月-2015年1月间来我院诊治的晚期结直肠癌患者64例,随机平均分为两组,分别给予替吉奥或卡培他滨联合奥沙利铂治疗,对其治疗效果进行对比分析。结果根据近期临床有效率评价标准,替吉奥联合奥沙利铂治疗组的总有效率为56.25%,卡培他滨联合奥沙利铂治疗组的总有效率为31.25%;治疗期间不良反应发生率,替吉奥联合奥沙利铂治疗组明显低于卡培他滨联合奥沙利铂治疗组。结论替吉奥联合奥沙利铂治疗晚期结肠直癌安全性较高、不良反应发生率较低、近期临床有效率较高,值得临床推广应用。
Objective To investigate the clinical efficacy of tegaserod or capecitabine in combination with oxaliplatin in the treatment of advanced colorectal cancer. Methods Sixty-four patients with advanced colorectal cancer diagnosed and treated in our hospital from January 2013 to January 2015 were randomly divided into two groups, treated with either tegaserod or capecitabine plus oxaliplatin, The treatment effect of comparative analysis. Results According to the recent clinical evaluation of clinical efficacy, the total effective rate for the treatment group of tegaserod combined with oxaliplatin was 56.25%, the total effective rate of capecitabine combined with oxaliplatin treatment group was 31.25%; adverse reactions during treatment The incidence of tirofiban plus oxaliplatin in the treatment group was significantly lower than that in the capecitabine plus oxaliplatin treatment group. Conclusion The treatment of advanced colorectal cancer with tegaserod combined with oxaliplatin is safe, the incidence of adverse reactions is low, and the clinical efficiency is high recently, which is worthy of clinical application.